Skip to main content

Advertisement

SpringerLink
Log in

Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Despite the lack of placebo-controlled trials, glucocorticoids are considered the mainstay of initial treatment for idiopathic inflammatory myopathy (IIMs) and myositis-associated ILD (MA-ILD). Glucocorticoid-sparing agents are often given concomitantly with other immunosuppressive agents, particularly in patients with moderate or severe disease. As treatment of refractory cases of idiopathic inflammatory myopathies has been challenging, there is growing interest in evaluating newer therapies including biologics that target various pathways involved in the pathogenesis of IIMs. In a large clinical trial of rituximab in adult and juvenile myositis, the primary outcome was not met, but the definition of improvement was met by most of this refractory group of myositis patients. Rituximab use was also associated with a significant glucocorticoid-sparing effect. Intravenous immune globulin (IVIg) can be used for refractory IIMs or those with severe dysphagia or concomitant infections. Anti-tumor necrosis factor (anti-TNF) utility in IIMs is generally limited by previous negative studies along with recent reports suggesting their potential for inducing myositis. Further research is required to assess the role of new therapies such as tocilizumab (anti-IL6), ACTH gel, sifalimumab (anti-IFNα), and abatacept (inhibition of T cell co-stimulation) given their biological plausibility and encouraging small case series results. Other potential novel therapies include alemtuzumab (a humanized monoclonal antibody which binds CD52 on B and T lymphocytes), fingolimod (a sphingosine 1-phosphate receptor modulator that traps T lymphocytes in the lymphoid organs), eculizumab, and basiliximab. The future investigations in IIMs will depend on well-designed controlled clinical trials using validated consensus core set measures and improvements in myositis classification schemes based on serologic and histopathologic features.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314–324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bunch TW, Worthington JW et al (1980) Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 92(3):365–369

    Article  CAS  PubMed  Google Scholar 

  3. Dalakas MC, Illa I, Dambrosia JM et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329(27):1993–2000

    Article  CAS  PubMed  Google Scholar 

  4. Miller FW, Leitman SF, Cronin ME et al (1992) Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 326(21):1380–1384

    Article  CAS  PubMed  Google Scholar 

  5. Troyanov Y, Targoff IN, Tremblay JL et al (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84(4):231–249

    Article  Google Scholar 

  6. Koenig M, Fritzler MJ, Targoff IN et al (2007) Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 9(4):R78

    Article  PubMed  PubMed Central  Google Scholar 

  7. Rider LG, Werth VP, Huber AM et al (2011) Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient/parent global activity, manual muscle testing (MMT), health assessment questionnaire (HAQ)/childhood health assessment questionnaire (C-HAQ), childhood myositis assessment scale (CMAS), myositis disease activity assessment tool (MDAAT), disease activity score (DAS), short form 36 (SF-36), child health questionnaire (CHQ), physician global damage, myositis damage index (MDI), quantitative muscle testing (QMT), myositis functional index-2 (FI-2), myositis activities profile (MAP), inclusion body myositis functional rating scale (IBMFRS), cutaneous dermatomyositis disease area and severity index (CDASI), cutaneous assessment tool (CAT), dermatomyositis skin severity index (DSSI), skindex, and dermatology life quality index (DLQI). Arthritis Care Res 63(Suppl 11):S118–S157

    Article  Google Scholar 

  8. Oddis CV, Rider LG, Reed AM et al (2005) International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52(9):2607–2615

    Article  PubMed  Google Scholar 

  9. Isenberg DA, Allen E, Farewell V et al (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43(1):49–54

    Article  CAS  Google Scholar 

  10. R Aggarwal, LG Rider, N Ruperto, N Bayat, B Erman, BM Feldman, A Huber, CV Oddis, I Lundberg, AA Amato, RG Cooper, H Chinoy, M Dastmalchi, D Fiorentino, D Isenberg, JD Katz, A Mammen, M de Visser, SR Ytterberg, D. Katalin, L Villa, M Rinaldi, H Rockette, P Lachenbruch, F Miller, J Vencovsky. A (2014) Consensus Hybrid Definition using a Conjoint Analysis is Proposed as Response Criteria for Minimal and Moderate Improvement in Adult Polymyositis and Dermatomyositis Clinical Trials. Arthritis Rheum 64(10 Suppl).

  11. Mahler EA, Blom M, Voermans NC et al (2011) Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 50(12):2206–2213

    Article  CAS  Google Scholar 

  12. Valiyil R, Casciola-Rosen L, Hong G et al (2010) Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res 62(9):1328–1334

    Article  CAS  Google Scholar 

  13. Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52(2):601–607

    Article  CAS  PubMed  Google Scholar 

  14. Mok CC, Ho LY, To CH (2007) Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 34(9):1864–1868

    CAS  PubMed  Google Scholar 

  15. Chung L, Genovese MC, Fiorentino DF (2007) A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143(6):763–767

    Article  CAS  PubMed  Google Scholar 

  16. Brulhart L, Waldburger JM, Gabay C (2006) Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 65(7):974–975

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF (2005) Efficacy of rituximab in refractory polymyositis. J Rheumatol 32(7):1369–1370

    PubMed  Google Scholar 

  18. Arlet JB, Dimitri D, Pagnoux C et al (2006) Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 16(5):334–336

    Article  PubMed  Google Scholar 

  19. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC (2014) RIM Study Group, Oddis CV. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66(3):740–749

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kalluri M, Oddis CV (2010) Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med 31:501–512

    Article  PubMed  Google Scholar 

  21. Marie I, Hachulla E, Chérin P et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47:614–622

    Article  CAS  PubMed  Google Scholar 

  22. Keir GJ, Maher TM, Ming D et al (2014) Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 19:353–359

    Article  PubMed  Google Scholar 

  23. Andersson H, Sem M, Lund MB, Aaløkken TM, Günther A, Walle-Hansen R, Garen T, Molberg Ø (2015) Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford) 54:1420–1428

    Article  Google Scholar 

  24. Cherin P, Pelletier S, Teixeira A et al (2002) Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 46(2):467–474

    Article  CAS  PubMed  Google Scholar 

  25. Danieli MG, Pettinari L, Moretti R, Logullo F, Gabrielli A (2011) Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 10(3):144–149

    Article  PubMed  Google Scholar 

  26. Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y (2012) GB-0998 Study Group. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol 22(3):382–393

    Article  CAS  PubMed  Google Scholar 

  27. Suzuki Y, Hayakawa H, Miwa S et al (2009) Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 187:201–206

    Article  CAS  PubMed  Google Scholar 

  28. Bakewell CJ, Raghu G (2011) Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest 139:441–443

    Article  PubMed  Google Scholar 

  29. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT (2012) Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 78(13):1009–1015

    Article  CAS  PubMed  Google Scholar 

  30. Iannone F, Scioscia C, Falappone PC et al (2006) Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 33(9):1802–1804

    CAS  PubMed  Google Scholar 

  31. Muscle Study Group (2011) A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70(3):427–436

    Article  Google Scholar 

  32. Hengstman GJ, van den Hoogen FH, Barrera P et al (2003) Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 50(1):10–15

    Article  CAS  PubMed  Google Scholar 

  33. Selva-O’Callaghan A, Martínez-Costa X, Solans-Laque R et al (2004) Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology (Oxford) 43(9):1196–1197

    Article  Google Scholar 

  34. Anandacoomarasamy A, Howe G, Manolios N (2005) Advanced refractory polymyositis responding to infliximab. Rheumatology (Oxford) 44(4):562–563

    Article  CAS  Google Scholar 

  35. Hengstman GJ, van den Hoogen FH, van Engelen BG (2004) Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol 52(1):61–63

    Article  CAS  PubMed  Google Scholar 

  36. Efthimiou P, Schwartzman S, Kagen LJ (2006) Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 65(9):1233–1236

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Dastmalchi M, Grundtman C, Alexanderson H et al (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67(12):1670–1677

    Article  CAS  PubMed  Google Scholar 

  38. Coyle K, Pokrovnichka A, French K (2008) A randomized double blind placebo controlled trial of infliximab in patients with polymyositis and dermatomyositis. Arthritis Res 58:S293

    Google Scholar 

  39. Hengstman GJ, De Bleecker JL, Feist E (2008) Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 59(3–4):159–163

    Article  CAS  PubMed  Google Scholar 

  40. Riolo G, Towheed TE (2012) Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J Rheumatol 39(1):192–194

    PubMed  Google Scholar 

  41. Klein R, Rosenbach M, Kim EJ et al (2010) Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 146(7):780–784

    Article  PubMed  PubMed Central  Google Scholar 

  42. Ishikawa Y, Yukawa N, Ohmura K et al (2010) Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol 29(5):563–566

    Article  PubMed  Google Scholar 

  43. Brunasso AM, Scocco GL, Massone C (2010) Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol 37(7):1549–1550

    Article  CAS  PubMed  Google Scholar 

  44. Lepidi H, Frances V, Figarella-Branger D et al (1998) Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 24(1):73–79

    Article  CAS  PubMed  Google Scholar 

  45. Gabay C, Gay-Croisier F, Roux-Lombard P et al (1994) Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 37(12):1744–1751

    Article  CAS  PubMed  Google Scholar 

  46. Lundberg I, Ulfgren AK, Nyberg P et al (1997) Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 40(5):865–874

    Article  CAS  PubMed  Google Scholar 

  47. Narazaki M, Hagihara K, Shima Y (2011) Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 50(7):1344–1346

    Article  Google Scholar 

  48. Kondo M, Murakawa Y, Matsumura T, Matsumoto O, Taira M, Moriyama M, Sumita Y, Yamaguchi S (2014) A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology (Oxford) 53(10):1907–1908

    Article  Google Scholar 

  49. Thompson B, Corris P, Miller JA et al (2008) Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol 35(10):2080–2082

    PubMed  Google Scholar 

  50. Murata K, Dalakas MC (1999) Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 155(2):453–460

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Nagaraju K, Raben N, Villalba ML, Danning C, Loeffler LA, Lee E, Tresser N, Abati A, Fetsch P, Plotz PH (1999) Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 92(2):161–169

    Article  CAS  PubMed  Google Scholar 

  52. Musuruana JL, Cavallasca JA (2011) Abatacept for treatment of refractory polymyositis. Joint Bone Spine 78(4):431–432

    Article  PubMed  Google Scholar 

  53. Arabshahi B, Silverman RA, Jones OY, Rider LG (2012) Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 160(3):520–522

    Article  PubMed  PubMed Central  Google Scholar 

  54. Maeshima K, Kiyonaga Y, Imada C, Iwakura M, Hamasaki H, Haranaka M, Ishii K (2014) Successful treatment of refractory anti-signal recognition particle myopathy using abatacept. Rheumatology (Oxford) 53(2):379–380

    Article  Google Scholar 

  55. Kerola AM, Kauppi MJ (2015) Abatacept as a successful therapy for myositis—a case-based review. Clin Rheumatol 34(3):609–612

    Article  PubMed  Google Scholar 

  56. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, Park P, Amato AA (2005) Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57(5):664–678

    Article  CAS  PubMed  Google Scholar 

  57. Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, Beggs AH, Amato AA, Greenberg SA (2007) Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 56(11):3784–3792

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, Ytterberg SR, Gregersen PK, Behrens TW, Reed AM (2007) An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 13(1–2):59–68

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, Ellingson S, Newman B, Bauer JW, Peterson EJ, Baechler EC, Reed AM (2009) Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 60(11):3436–3446

    Article  CAS  PubMed  Google Scholar 

  60. Higgs BW, Zhu W, Morehouse C et al (2014) A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 73(1):256–262

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Myositis Center and Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, 3601 5th Avenue, Suite 2B, Pittsburgh, PA, 15261, USA

    Siamak Moghadam-Kia, Chester V. Oddis & Rohit Aggarwal

Authors
  1. Siamak Moghadam-Kia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chester V. Oddis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rohit Aggarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rohit Aggarwal.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moghadam-Kia, S., Oddis, C.V. & Aggarwal, R. Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics. Clinic Rev Allerg Immunol 52, 81–87 (2017). https://doi.org/10.1007/s12016-016-8530-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-016-8530-2

Keywords

Search

Navigation